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Abstract
Background: Well-developed and well-tested patient-reported outcome measures for
non–muscle-invasive bladder cancer (NMIBC) are required.
Objective: To test and adapt the scale structure and explore the psychometric properties
of the European Organisation for Research and Treatment of Cancer (EORTC) question-
naire for NMIBC.
Design, setting, and participants: A total of 433 patients in the Bladder COX-2 Inhibition
Trial (BOXIT) completed the EORTC QLQ-C30 and NMIBC questionnaires. BOXIT is
evaluating the addition of celecoxib to standard treatment in high- and intermedi-
ate-risk NMIBC.
Outcome measurements and statistical analysis: Multitrait scaling investigated and
adapted the questionnaire scale structure and evaluated the reliability and validity of
the revised scales, as well as responsiveness to change.
Results and limitations: A total of 410 patients (94.7%) (79.3% men, 74.6% high risk)
returned baseline forms, and the questionnaire response rate was 88.2%. Multitrait
scaling conﬁrmed six scales and ﬁve single items. Scales and items demonstrated
signiﬁcant differences between patients with good and poor performance status scores
(p < 0.001). Men reported better sexual function than women ( p < 0.001). Scale and
single-itemmodule scores were not highly correlated with QLQ-C30 scores (evidence of
discriminant validity), and the module was responsive to changes in health over time.
International and test–retest data are required.
Conclusions: This study demonstrates the evidence-driven adapted scale structure and
psychometric data of the EORTCQLQ-NMIBC24module to use in clinical trials of patients
with high- or intermediate-risk bladder cancer.
# 2014 European Association of Urology. Published by Elsevier B.V. Open access under 
.CC BY-NC-ND license* Corresponding author. University Hospitals NHS Foundation Trust, Bristol Royal Inﬁrmary,
ristol, Avon BS2 8HW, UK.
eby@bris.ac.uk (J.M. Blazeby).Upper Maudlin Street, B
E-mail address: j.m.blazhttp://dx.doi.org/10.1016/j.eururo.2014.02.034
0302-2838 # 2014 European Association of Urology. Published by Elsevier B.V. Open access under CC BY-NC-ND license.
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The majority of patients with bladder cancer (BCa) present
with non–muscle-invasive BCa (NMIBC) and aremanaged by
endoscopic resection alone plus immediate postoperative
intravesical chemotherapy [1]. Depending on risk stratifica-
tion, intravesical immunotherapy with bacillus Calmette-
Gue´rin (BCG) or chemotherapy using mitomycin C (MMC)
may be considered. Evaluation of current treatments today
typically includes assessment of patient-reported outcomes
(PROs) in addition to clinical end points. PROs are defined as
outcomes from the patients themselves that are not
interpreted by an observer [2]. Measurement of PROs is
most commonly undertaken with questionnaires, and the
EuropeanOrganisation for Research and Treatment of Cancer
(EORTC) QLQ-C30 and the Functional Assessment of Cancer
Therapy measures are widely used. Both assess generic
aspects of health and symptoms that commonly occur
with cancer [3–6]. Measures may be supplemented by
disease-specific modules to address concerns in specific
cancer sites.
In the 1990s, the EORTC Quality of Life Group developed
modules for BCa, the QLQ-BLS24 for superficial BCa (NMIBC)
and the QLQ-BLM30 for muscle-invasive BCa [7]. Both
modules have been used in clinical studies, but formal
validation data are lacking. The aim of this study was to[(Fig._1)TD$FIG]
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Fig. 1 – Trial schema with timing of assessments using the EORTC QLQ-C30 and
BOXIT = Bladder COX-2 Inhibition Trial; NMIBC = non–muscle-invasive bladderexamine the scale structure, reliability, and clinical validity
of the QLQ-BLS24 in patients with NMIBC.
2. Methods
Patients participating in the Bladder COX-2 Inhibition Trial (BOXIT; CR
UK/07/004; ISRCTN: 84681538) were recruited. BOXIT is a randomised
placebo-controlled trial evaluating the addition of celecoxib to standard
treatment (transurethral resection of bladder tumour, single-dose MMC,
and BCG induction and maintenance for disease at high risk for
recurrence or multiple MMC instillations for disease at intermediate risk
for recurrence [8]). Patients with primary or recurrent NMIBC at high or
intermediate risk of recurrence according to the 2002 European
Association of Urology guidelines were eligible and include Tis, T1,
and Ta tumours other than those at low risk [9]. The interventions in
BOXIT were administered according to the study protocol [8].
2.1. Questionnaires
Patients completed the QLQ-C30 questionnaire and the QLQ-BLS24
module before treatment in a clinic and at regular intervals thereafter.
In thehigh-riskgroups, questionnaireswere completedat timepoint0and
at 2, 3, 6, and 12 mo. In the intermediate-risk group, assessments were
completed at time point 0 (before randomisation) and at 12 mo (Fig. 1).
Missing data were imputed according to the EORTC guidelines, and
questionnaires were considered as missing if >50% of the items were
missing [4]. Using this approach, some missing items still could not be
imputed, but the other data from these questionnaires were still used.urrent high- or
NMIBC eligible for
XIT
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QLQ-NMIBC24.
cancer; PRO = patient-reported outcome.
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 1 1 4 8 – 1 1 5 61150Response rates (based on entirely missing questionnaires or unusable
questionnaire) at each time point were examined and reasons for missing
questionnaires documented. Response rates to the sexual items were
calculated based on whether patients reported being at least ‘‘a little’’
sexually active (item 48).
The module was developed according to standard EORTC Quality of
Life Group guidelines, and translations followed standard procedures [4].
The module has 24 items originally hypothesised to form multi-item
scales assessing urinary symptoms (items 1–7), intravesical treatment
issues (items 10 and 11), future perspective (items 12–14), fever and
feeling ill (items 8 and 9), and abdominal bloating and ﬂatulence (BAF)
(items 15 and 16), along with single items addressing different aspects of
sexual functioning (items 17–24). All responses are linearly transformed
from0 to 100,with a high score indicatingmore symptomsor problems or
better function for the functional scales. Ethics committee approval and
written informed consent were obtained. The sample was determined by
the patients within the BOXIT study up until November 2012.
2.2. Defining the scales within the module
Multitrait scaling analyses with data from each of the time points
examined whether the individual items may be grouped into the
hypothesised scales. The items assessing sexual functioning included
two items to be completed by all patients, two items for completion by
men only, and one item for completion by women only; also, there were
three items completed by men or women reporting to be sexually activeTable 1 – Clinical details and questionnaire response rates
Clinical details All patients,
n = 410
Age, yr, mean (SD) 66.7 (9.3)
Age, yr, range 35–91
Gender male, no. (%) 325 (79.3)
Tumour grade, no. (%)
G1 19 (4.6)
G2 149 (36.3)
G3 209 (51.0)
Unknown 33 (8.1)
Tumour stage, no. (%)
Ta 167 (40.7)
T1 167 (40.7)
Tis 45 (11.0)
Ta/Tis 17 (4.1)
T1/Tis 14 (3.4)
Smoking status, no. (%)
Current 127 (31.0)
Previous 213 (52.0)
Never 60 (14.6)
Diabetes present, no. (%) 32 (7.8)
Questionnaire response rates, no. (%)
Baseline 401 (97.8)
2 mo* 282 (92.2)
3 mo* 288 (94.1)
6 mo* 263 (85.9)
12 mo 298 (86.1)
Response rate to sexual scales/items, no. (%)**
Sexual function 1424 (93.0)
Male sexual problems 1055 (85.8)
Sexual intimacy 505 (76.6)
Risk of contamination 504 (76.5)
Sexual enjoyment 498 (75.6)
Female sexual problems 70 (79.5)
N/A = not available; SD = standard deviation.
* Denominator for 2-, 3-, and 6-mo time points is 306 (high-risk patients only).
** Response rates for patients who are sexually active at each time point.in the past 4 wk. Given the conditional nature of many of these items, it
was not possible to analyse them as one scale.
Statistical evidence of item convergent validity was deﬁned as a
correlation of 0.40 between an item and its own scale (corrected for
overlap) [10]. Item discriminant validity was deﬁned as a correlation of
<0.40 between an item and other scales in the questionnaire. An item
was considered to be a scaling success when the correlation between the
item and its own scale was greater than its correlation with any other
scale. For each scale, the ceiling and ﬂoor effects were examined. After
ﬁnalising the scale structure, other tests were performed.
2.3. Evaluating the reliability and validity of the module
The internal consistency was assessed by the Cronbach a coefﬁcient,
with >0.70 considered acceptable for group comparisons being
examined within each scale at each assessment point [11].
Known group comparisons evaluated whether the module was able
to discriminate between subgroups of patients differing in clinical status
[11]. Known groups used for this comparison were baseline differences
in QLQ-C30 physical function scores, with <90 or >90 representing
relatively high (better) or relatively low (worse) scores, respectively. It
was hypothesised that the scale scores of the QLQ-BLS24 would be
higher (show more problems) in patients with lower physical function.
Additional exploratory known groups validity testing was performed
comparing data frommen versuswomen. The independent student t test
was used to examine differences in mean scores. Effect sizes wereHigh risk,
n = 306
Intermediate risk,
n = 104
66.6 (9.7) 66.8 (7.8)
35–91 35–87
247 (80.7) 78 (75.0)
3 (1.0) 16 (15.4)
61 (19.9) 88 (84.6)
209 (68.3) 0 (0.0)
33 (10.7) 0 (0.0)
78 (25.5) 89 (85.6)
152 (49.7) 15 (14.4)
45 (14.7) 0 (0.0)
17 (5.6) 0 (0.0)
14 (4.6) 0 (0.0)
102 (33.3) 25 (24.0)
159 (52.0) 54 (51.9)
36 (11.8) 24 (23.1)
22 (7.2) 10 (9.6)
298 (97.4) 103 (99.0)
282 (92.2) N/A
288 (94.1) N/A
263 (85.9) N/A
217 (94.3) 81 (77.9)
1248 (92.6) 176 (95.7)
930 (85.1) 125 (91.9)
445 (77.0) 60 (74.1)
444 (76.8) 60 (74.1)
439 (76.0) 59 (72.8)
57 (78.1) 13 (86.7)
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E U R O P E AN URO L OGY 6 6 ( 2 0 1 4 ) 1 1 4 8 – 1 1 5 6 1151expressed as the mean difference divided by the pooled standard
deviation (SD). Effect sizes were interpreted using the Cohen rule of
thumb that a change of 0.5 SD represents amoderate effect, and a change
>0.8 SD is a large effect [12].
To assess validity, correlations between the scales of the QLQ-BLS24
module and the scales of the QLQ-C30 were made using baseline data.
Polychoric correlations were calculated, as is appropriate for items with
four response categories. The responsiveness of themodule to changes in
health over time was examined in high-risk patients who underwent
intensive treatments. It was hypothesised that during treatment,
patients would report increased urinary symptoms and decreased
generic aspects of health. Pairwise comparisons of changes in mean
scores from baseline to 2, 3, 6, and 12mowere evaluated using t tests for
correlated samples. Because multiple comparisons were performed, a
cautious but uncorrected p value of <0.01 was considered to be
statistically signiﬁcant.
All analyses were performed using Stata/IC statistical software
(release 12, 2009; StataCorp LP, College Station, TX, USA).
3. Results
3.1. Patient characteristics, response rates, and missing data
At the time of data analyses, 472 patients were randomised,
433 patients consented to the quality-of-life study, and
410 of them completed a baseline questionnaire. Of these
patients, 401 (97.8%) had complete baseline PRO data sets.
The majority (79.3%) were men, and more than two-thirds
hadhigh-risk tumours (n = 306, 74.6%) (Table 1). Thenumber
ofquestionnaires returnedat each timepointandcompletion
rates were 282 (92.2%), 288 (94.1%), 263 (85.9%), and 298
(94.3%) at 2, 3, 6, and 12 mo, respectively, for the high-risk
group; at 12mo, 81 questionnaires (77.9%)were returned for
the intermediate-risk group. There were therefore 1532
questionnaires in total, with a completion rate for the five
assessment points of 88.2%. At baseline, 48% of patients
reported at least a little sexual activity (item 48), meaning
that completion rates for the sexual scales and items were
generallygood(>75%).Sociodemographicandclinical details
and questionnaire response rates are shown in Table 1.
3.2. Defining the scales in the module
Final results of the multitrait scaling analyses are shown in
Table 2. Item within scale correlations in the original
hypothesised urinary symptom, fever and malaise, and
sexual function scales were all 0.40, and therefore these
scales were maintained. Items 40 and 41, addressing
intravesical treatment issues, showed many scaling errors.
Discussionwithin the trialmanagement group therefore led
to agreement to include item 40 as a single item assessing
intravesical treatment issues. Item 41 correlated well with
the future perspectives scale, and therefore this scale was
expanded to a four-item future worries scale (items 41–44).
The two items assessing abdominal BAF (items 45 and 46)
demonstrated satisfactory scaling properties when com-
bined and thus formed a scale. The scale concerning sexual
problems in men, items 49 and 50, functioned well and was
retained. The remaining items in the original sexual
function scale about sexual intimacy (item 51), risk of
Table 3 – The scale structure of the EORTC QLQ-NMIBC24y
Originally hypothesised
scales in the QLQ-BLS24
Items in each scale Revised scales and single
items in the QLQ-NMIBC24
Numbers of items in
each scale/item
Urinary symptoms 31–37 Urinary symptoms 31–37
Malaise 38, 39 Malaise 38, 39
Intravesical treatment issues 40, 41 Intravesical treatment issues 40
Future worries 42–44 Future worries 41–44
Bloating and ﬂatulence 45, 46 Bloating and ﬂatulence 45, 46
Sexual function* 47–54 Sexual function** 47, 48
Male sexual problems 49, 50
Sexual intimacy 51
Risk of contaminating a partner 52
Sexual enjoyment** 53
Female sexual problems 54
Scoring a high score is equivalent to more problems.
y Figure 2 shows the full questionnaire.
* Individual items.
** Scoring a high score is equivalent to better function.
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 1 1 4 8 – 1 1 5 61152contamination of partner (item 52), sexual enjoyment
(item 53), and an item for sexual function in women only
(item 54) remained as individual items.
At baseline, the revised scales showed some floor effects
(as expected), because side-effects of treatment would be
limited at that stage (scales for malaise, intravesical
treatment >72% reported no problems at all). At all time
points, few ceiling effects were noted (<2.5% for each scale;
data not shown).Table 4 – Mean patient-reported outcome scores in the QLQ-C30 and QL
and between men and women
Scale/item PF >90, n = 284,
mean (SD)
PF <90, n = 110,
mean (SD)
p val
(t tes
Functional scales, QLQ-C30*
PF 98.8 (2.6) 77 (13.5) <0.00
Role function 96.5 (11.0) 77.7 (26.3) <0.00
Emotional function 89.8 (13.7) 77.8 (21.0) <0.00
Cognitive function 92.1 (11.5) 82.3 (18.2) <0.00
Social function 92.6 (14.7) 77.5 (25.7) <0.00
Global quality of life 83.5 (16.4) 67.3 (17.7) <0.00
Symptom scales, QLQ-C30**
Pain 5.6 (11.7) 24.8 (26.2) <0.00
Fatigue 7.9 (12.0) 27.4 (18.8) <0.00
Nausea and vomiting 0.6 (3.4) 3.9 (11.7) <0.00
Module scales 24**
Urinary symptoms 19.2 (17.0) 32.1 (21.1) <0.00
Malaise 1.3 (5.3) 6.1 (13.0) <0.00
Future worries 31.4 (23.0) 36.4 (26.2) 0.06
Bloating and ﬂatulence 14.0 (17.2) 17.7 (18.0) 0.05
Sexual function 27.3 (24.5) 13.7 (18.2) <0.00
Male sexual problemsa
(BL(BLSSXmen)
19.6 (27.6) 31.5 (36.2) 0.00
Module single items**
Intravesical treatment 8.5 (15.9) 13.1 (18.2) 0.01
Sexual intimacyb 9.1 (19.4) 20.6 (35.8) 0.01
Risk of contaminationb 19.1 (26.8) 17.8 (30.0) 0.81
Sexual enjoymentb 67.5 (30.1) 43.3 (32.9) 0.00
Female sexual problemsc 22.9 (26.4) 20.8 (35.4) 0.87
NA = not available; PF = physical function; SD = standard deviation.
# Effect size is mean difference divided by standard deviation.
* A higher score means better function.
** A high score means more symptoms or worse problems.
a Total number of respondents was 288 (91.1%).
b Total number of respondents was 128 (73%) answering questions about sexual
c Total number of respondents was 19 females (79%) answering questions aboutThe original hypothesised scales in the EORTC QLQ-BLS24
and the confirmed scales in the EORTC QLQ-NMIBC24 are
shown in Table 3.
3.3. Reliability
The internal consistency of the scales at each time point
were good (>0.70) for the urinary symptoms, future
worries, sexual function, and sexual function in men scales.Q-NMIBC24 between patients with high and low performance status
ue
t)
Effect
size#
Male, n = 316,
mean (SD)
Female, n = 85,
mean (SD)
p value
(t test)
Effect
size#
01 2.94 93.3 (12.6) 90.5 (11.0) 0.066 0.23
01 1.12 90.9 (19.8) 92.2 (13.8) 0.588 0.07
01 0.75 86.9 (17.1) 84.0 (16.6) 0.160 0.17
01 0.72 89.4 (14.2) 89.3 (15.0) 0.962 0.01
01 0.81 87.6 (20.9) 92.0 (13.0) 0.066 0.23
01 0.98 79.5 (19.2) 77.9 (14.4) 0.498 0.08
01 1.13 11.0 (19.2) 10.6 (18.3) 0.858 0.02
01 1.38 12.6 (16.9) 16.3 (15.6) 0.070 0.22
01 0.49 1.7 (7.9) 1.4 (4.6) 0.713 0.05
01 0.71 23.8 (20.0) 19.6 (14.9) 0.072 0.22
01 0.59 2.6 (8.6) 2.6 (7.5) 0.949 0.01
6 0.21 33.0 (24.1) 32.3 (23.8) 0.830 0.03
5 0.22 14.2 (17.0) 17.8 (18.7) 0.090 0.21
01 0.60 26.5 (24.0) 11.9 (18.5) <0.0001 0.64
6 0.40 22.5 (30.3) NA 0.795 0.17
3 0.28 10.5 (17.3) 6.8 (13.5) 0.070 0.22
2 0.49 10.8 (22.6) 14.1 (30.1) 0.518 0.14
4 0.05 20.2 (28.5) 13.0 (24.1) 0.254 0.26
02 0.79 65.4 (32.4) 49.3 (26.3) 0.025 0.51
2 0.07 NA NA NA NA
intimacy, risk of contamination, and sexual enjoyment.
female sexual problems.
Table 5 – Validity–polychoric correlations between scales in the QLQ-C30 and the QLQ-NMIBC24
QLQ-C30 scales Urinary symptoms Malaise Future worries Bloating and ﬂatulence Sexual function Sexual problems in men
Physical function 0.29 0.28 0.07 0.10 0.33 0.22
Role function 0.41 0.61 0.24 0.22 0.14 0.34
Emotional function 0.25 0.39 0.50 0.32 0.01 0.08
Cognitive function 0.29 0.31 0.16 0.29 0.14 0.24
Social function 0.43 0.52 0.34 0.15 0.20 0.26
Global quality of life 0.37 0.46 0.37 0.21 0.01 0.04
Pain 0.44 0.47 0.18 0.33 0.09 0.24
Fatigue 0.36 0.71 0.27 0.33 0.18 0.24
Nausea and vomiting 0.26 0.59 0.15 0.35 0.12 0.21
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0.76; in the abdominal bloating scale, this ranged between
0.49 and 0.62 (Table 2).
3.4. Clinical validity
Patientswithhigh scores (>90)on thephysical functionscale
of theQLQ-C30 reportedsignificantlybetter functional scores
and fewer symptomsonallQLQ-C30and threemodule scales
(urinary symptoms, malaise, and sexual function) and on a
single item (sexual enjoyment) than patients with poorer
physical functioning (p < 0.001, Table 4). The effect sizes for
these differences were moderate to large. Most scales and
items were similar between men and women, except thatTable 6 – Responsiveness to change over timey
Function* Baseline 2 mo p value 3 mo
Physical* 92.9 89.9 <0.001 90.3
Role* 91.1 84.1 <0.001 86.8
Emotion* 86.7 84.9 0.097 85.0
Cognitive* 89.0 86.0 0.002 86.3
Social* 88.0 85.5 0.046 87.8
Global QOL* 78.5 75.1 0.003 75.7
Symptoms
Fatigue 10.8 15.7 <0.001 19.2
N&V 13.7 21.3 <0.001 3.3
Pain 1.7 3.0 0.040 13.8
Dyspnoea 6.3 10.2 0.001 10.2
Sleep 18.0 20.4 0.115 19.2
Appetite 3.0 5.9 0.001 4.6
Cons 8.5 9.0 0.684 10.2
Diarrhoea 4.5 6.4 0.087 6.5
NMIBC24
Urinary 23.4 26.2 0.040 22.8
Malaise 3.1 9.3 <0.001 5.9
Future worries 33.3 30.0 0.011 29.3
BAF 14.5 20.6 <0.001 18.2
SX 24.2 23.5 0.514 26.2
SXmen 22.4 28.1 0.016 24.2
Intravesical 10.1 12.5 0.094 10.2
SXI** 11.0 16.2 0.083 13.1
SXCP** 20.4 32.4 0.001 18.5
SXEN*,** 70.7 64.0 0.707 67.5
SXfem** 26.7 30.0 0.591 33.3
BAF = bloating and ﬂatulence; Cons = constipation; N&V = nausea and vomiting;
partner; SXEN = sexual enjoyment; SXfem = sexual function in women; SXI = sex
A high score means more problems except in function scales, in which a high sc
* Function scales, in which a high score is equivalent to better function.
y Mean QLQ-C30 and NMIBC24 scores before and after treatment in high-risk pa
** The number of responders varies according to subgroup and month; for exammen reported significantly more problems with sexual
function (p = 0.005) than women (Table 4).
3.5. Criterion validity
The correlations between the majority of the scales in
the core questionnaire and module (n = 44, 88%) were
relatively low (r < 0.40, Table 5), indicating that the
module is not overlapping in content with the QLQ-C30.
Correlations >0.4 were observed between the malaise
scale in the new module and role and social function
scales, global quality of life, and the pain, fatigue, and
nausea and vomiting scales in the QLQ-C30. The urinary
symptoms scale was moderately associated with rolep value 6 mo p value 12 mo p value
<0.001 89.8 <0.001 89.7 <0.001
<0.001 84.9 <0.001 87.2 0.008
0.107 86.8 0.877 87.2 0.757
0.002 86.0 0.001 86.5 0.001
0.452 87.3 0.238 87.8 0.301
0.016 74.2 0.003 74.9 0.001
0.033 14.7 0.007 13.3 0.039
<0.001 20.2 <0.001 18.3 <0.001
<0.001 2.8 0.008 3.0 0.002
<0.001 10.5 <0.001 9.6 0.002
0.341 22.1 0.006 20.7 0.004
0.058 5.7 0.012 5.2 0.070
0.072 11.1 0.043 9.2 0.191
0.067 6.7 0.107 6.0 0.347
0.4389 23.9 0.913 22.3 0.916
0.001 5.8 0.004 5.1 0.035
0.002 28.2 0.001 26.1 <0.001
0.001 20.0 <0.001 19.9 <0.001
0.594 26.4 0.293 25.9 0.892
0.147 25.4 0.149 28.8 0.006
0.739 10.7 1.000 9.6 0.416
0.549 13.0 0.311 8.2 0.497
0.892 18.6 0.883 15.6 0.0132
0.236 67.1 0.083 69.9 0.311
0.594 48.1 0.0956 33.3 0.604
QOL = quality of life; SX = sexual function; SXCP = risk of contamination of
ual intimacy; SXmen = sexual problems in men.
ore is equivalent to better function.
tients (n = 260).
ple, month 2 versus baseline had 157 men and 10 females.
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 1 1 4 8 – 1 1 5 61154(0.41) and social function (0.43) and the pain scales (0.44)
in the QLQ-C30, and the future worries scale in the
module showed a moderate association with the emo-
tional function scale (0.50).
3.6. Responsiveness to changes over time
Table 6 shows change in scores before and after treatment.
Although little increase in urinary symptoms was observed
during the follow-up period, several aspects of health
[(Fig._2)TD$FIG]
EORTC  QLQ–NMIBC24    
Patients sometimes report that they have the following s
which you have experienced these symptoms or problem
the number that best applies to you. 
During the past week: 
31. Have you had to urinate frequently during the day? 
32. Have you had to urinate frequently at night? 
33. When you felt the urge to pass urine, did you have 
get to the toilet? 
34. Was it difficult for you to get enough sleep, because
needed to get up frequently at night to urinate?
35. Have you had difficulty going out of the house, beca
needed to be close to a toilet? 
36. Have you had any unintentional release (leakage) o
37. Have you had pain or a burning feeling when urinat
38. Did you have a fever?  
39. Did you feel ill or unwell? 
40. Did you have trouble arranging your life around the
bladder treatment appointments (cystoscopies or instilla
41. Did you worry about having repeated bladder treatm
(cystoscopies or instillations)?  
42. Were you worried about your health in the future? 
43. Did you worry about the results of examinations and
44. Did you worry about possible future treatments? 
45. Did you have a bloated feeling in your abdomen? 
46. Have you had flatulence or gas? 
47. To what extent were you interested in sex? 
48. To what extent were you sexually active (with or wit
intercourse)?
49. For men only: Did you have difficulty gaining or mai
erection? 
50. For men only: Did you have ejaculation problems (e
ejaculation)?
51. Have you felt uncomfortable about being sexually in
52. Have you worried that you may contaminate your p
sexual contact with the bladder treatment you have bee
53. To what extent was sex enjoyable for you?  
54. For Women only: did you have a dry vagina or othe
during intercourse? 
Questionnaires are available from the EORTC Quality of Life Group (www.E
Fig. 2 – The European Organization for Research and Treatmentmeasured by both the QLQ-C30 and the module did
deteriorate during the first year of treatment. Significantly
poorer physical, role, and cognitive function scores and
worse nausea and vomiting and dyspnoea were seen at all
time points. These findings were reflected in worse global
quality-of-life scores at most assessments. Problems with
malaise and abdominal bloating were observed at most
follow-up assessments.
The finalmodulewas renamed the EORTCQLQ-NMIBC24
in keeping with current terminology (Fig. 2).ymptoms or problems. Please indicate the extent to 
s during the past week. Please answer by circling 
Not at 
all 
A
little 
Quite
a bit 
Very 
much 
4 3 2 1  
4 3 2 1 
to hurry to 4 3 2 1 
 you 4 3 2 1 
use you 4 3 2 1 
4 3 2 1 f urine? 
ing? 4 3 2 1 
4 3 2 1 
4 3 2 1 
 repeated 
tions)? 
4 3 2 1 
ents 4 3 2 1 
4 3 2 1 
 tests? 43 2 1
4 3 2 1 
4 3 2 1 
4 3 2 1 
4 3 2 1 
hout sexual 1 2 3 4
ntaining an 1 2 3 4
.g. dry 4 3 2 1 
4 3 2 1 timate? 
artner during 
n receiving? 1 2 3 4
4 3 2 1 
r problems 4 3 2 1 
ORTC.be/qol/). Copy right EORTC Quality of Life Group
of Cancer module for non–muscle-invasive bladder cancer.
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This study evaluated the EORTC questionnaire module for
NMIBC. An evidence-driven adaptation of the original scale
structure into a revised module with six scales (urinary
symptoms, malaise, future worries, bloating and flatulence,
sexual function, and male sexual problems) and five single
items was undertaken. Testing of the revised module
yielded data supporting its clinical, construct, and criterion
validity and acceptability of the module to patients
(completion rates were high, with minimal missing data).
The module was responsive to changes in health over time
and was renamed the EORTC QLQ-NMIBC24 to reflect
current terminology.
The purpose of measuring PROs in clinical trials
alongside standard end points is to generate information
to inform patients and their physicians about how
treatments affect quality of life [13,14]. This information
can supplement clinical outcome data in decision making.
While some studies have examined PROs of treatment for
BCa, there is a lack of data using condition-specific
questionnaire modules [15,16]. Condition-specific mea-
sures are available for many cancer sites, and this module
will add to the portfolio [3–6].
Although this was a large prospective study, it does
have its limitations; primarily, it was performed within a
single clinical trial and country. This study used clinical
evidence to drive andmake smallmodifications to the scale
structure of the questionnaire. Furtherwork examining the
additional measurement properties of the questionnaire in
other settings is still needed, including assessments
of test–retest reliability and other clinical validation
(eg, whether the module distinguishes between NMIBC
and muscle-invasive disease). It is also necessary to
examine the measurement properties of the module in
patients with low-risk NMIBC.
There were very few problems with missing question-
naires, indicating that the module is acceptable for patients
in a clinical trial. There were, however, more missing data
for the items addressing sexual function. Health-related
quality-of-life issues related to sexual function are assessed
in a number of EORTC modules, and work is ongoing to
develop a unified and comprehensive approach to assessing
sexual issues in trials in oncology.
This study used an evidence-driven approach to adapt
the scale structure of the EORTC module for NMIBC and
explored its psychometric properties in a cohort of UK
patients. Further testing in an international setting is still
needed.
5. Conclusions
The revised module has well-defined scales and items, is
acceptable for patients, and has encouraging psychometric
properties. The questionnaires may be obtained by con-
tacting the EORTC Quality of Life Department [4]. It is
recommended that the module be used as a supplement
to the QLQ-C30 in clinical trials to assess PROs in patients
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